LGD-4033, also known as Ligandrol, is a selective androgen receptor modulator (SARM) that was first developed by Ligand Pharmaceuticals in the early 2000s. The compound was initially designed as a potential treatment for muscle wasting and bone loss associated with aging, cancer, and other conditions that cause muscle and bone loss.

Ligand Pharmaceuticals developed LGD-4033 as a non-steroidal alternative to anabolic steroids. Anabolic steroids were originally developed to treat muscle and bone wasting conditions, but they are associated with serious side effects, such as liver damage, acne, and hair loss. SARMs, on the other hand, were designed to have fewer side effects by selectively targeting the androgen receptors in muscle and bone tissue.

LGD-4033 was first described in a patent application in 2005. The patent application described LGD-4033 as a compound that was effective in increasing muscle mass and bone density in animal models. The patent application also described the compound as having potential therapeutic uses in treating muscle wasting, osteoporosis, and other conditions associated with muscle and bone loss.

After the initial patent application, LGD-4033 was further developed and tested in animal models. In a study published in the Journal of Pharmacology and Experimental Therapeutics in 2007, researchers found that LGD-4033 was effective in increasing muscle mass and bone density in castrated male rats. The researchers also found that the compound was well-tolerated, with no observed toxicity or adverse effects.

Based on these promising results, Ligand Pharmaceuticals further developed LGD-4033 as a potential therapeutic for muscle and bone wasting conditions. In 2013, Viking Therapeutics acquired the rights to LGD-4033 from Ligand Pharmaceuticals, with the goal of developing the compound as a treatment for hip fracture.

Since then, LGD-4033 has gained popularity in the fitness and bodybuilding communities as a performance-enhancing drug. The compound is often marketed as a legal alternative to anabolic steroids, with claims of increased muscle mass, strength, and endurance.

However, the use of LGD-4033 as a performance-enhancing drug is not without controversy. In 2019, the World Anti-Doping Agency (WADA) added LGD-4033 to its list of banned substances. The use of LGD-4033 is prohibited in competition, and athletes who test positive for the compound can face suspension and other penalties.

Despite the controversy surrounding its use as a performance-enhancing drug, LGD-4033 continues to be studied as a potential therapeutic for muscle and bone wasting conditions. In a study published in the Journal of Cachexia, Sarcopenia and Muscle in 2020, researchers found that LGD-4033 was effective in increasing muscle mass and strength in older men with muscle wasting. The researchers also found that the compound was well-tolerated, with no observed adverse effects.

In conclusion, LGD-4033 is a SARM that was developed in the early 2000s as a potential treatment for muscle and bone wasting conditions. The compound has since gained popularity in the fitness and bodybuilding communities as a performance-enhancing drug, but its use is banned in competition by WADA. Despite the controversy surrounding its use as a performance-enhancing drug, LGD-4033 continues to be studied as a potential therapeutic for muscle and bone wasting conditions.